Search clinical trials for: Tysabri® (natalizumab)

Total 13891 results

Biogen
Elan Pharmaceuticals; United BioSource, LLC

Completed

JC-Virus (JCV) Antibody Program (STRATIFY-1)

Multiple Sclerosis

United States
University of South Florida

Completed

The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis (Tysex)

Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients (TIMER)

Relapsing Remitting Multiple Sclerosis (RRMS)

Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
Biogen
Elan Pharmaceuticals

Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Biogen

Completed

Tysabri Observational Program (TOP)

Relapsing-Remitting Multiple Sclerosis

Belgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
Biogen

Completed

Clinical Disease Activity With Long Term Natalizumab Treatment

Relapsing-Remitting Multiple Sclerosis

Czechia, Belgium
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Biogen
Elan Pharmaceuticals

Withdrawn

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Crohn's Disease
Biogen

Completed

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (STRATIFY-2)

Relapsing Multiple Sclerosis

United States, Puerto Rico
University Hospital, Caen
Biogen

Completed

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort (RELEVANT)

Multiple Sclerosis, Relapsing-Remitting

France
Biogen

Completed

Ireland Natalizumab (TYSABRI) Observational Program (iTOP)

Relapsing-Remitting Multiple Sclerosis

Ireland
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
Biogen
Elan Pharmaceuticals

Completed

Natalizumab Re-Initiation of Dosing

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Biogen

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (TRUST)

Relapsing-Remitting Multiple Sclerosis
Biogen

Terminated

Natalizumab Subcutaneous Immunogenicity and Safety Study (SIMPLIFY)

Relapsing Multiple Sclerosis

Belgium
Biogen

Terminated

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring (INFORM)

Crohn's Disease

United States, Puerto Rico
Biogen

Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab (PROTYS)

Multiple Sclerosis

Switzerland
Biogen

Completed

Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri

Multiple Sclerosis
Cornerstone Health Care, PA
Biogen

Completed

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
Biogen

Terminated

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (ESCALATE)

Relapsing Multiple Sclerosis

United States
Biogen

Completed

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke (ACTION)

Acute Ischemic Stroke

Spain, United States, Germany
Biogen

Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Japan
Biogen
Elan Pharmaceuticals

Terminated

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Rheumatoid Arthritis
Biogen

Completed

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (Tysabri Japan)

Multiple Sclerosis

Japan
Biogen

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)

Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Germany, Belgium
Biogen

Active, not recruiting

A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants (SATURATE-MS)

Multiple Sclerosis

Germany
Biogen

Active, not recruiting

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis

United States
Phoenix Neurological Associates, LTD

Unknown

Natalizumab in Inclusion Body Myositis (IBM) (IBM-NAT)

Inclusion Body Myositis (IBM)

United States
Biogen

Completed

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy (OPUS)

Epilepsy, Focal Seizures, Partial Seizures

United States
University of Chicago
Biogen

Completed

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

Multiple Sclerosis

United States
University at Buffalo
Biogen

Completed

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

Natalizumab High Titer Immunogenicity and Safety

Multiple Sclerosis

United States
Berkovich, Regina MD, PhD Inc.
Biogen; Cedars-Sinai Medical Center

Recruiting

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Rigshospitalet, Denmark
University of Copenhagen; Biogen; Copenhagen University Hospital, Hvidovre; Signifikans...

Completed

Natalizumab Treatment of Progressive Multiple Sclerosis (NAPMS)

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Denmark
Biogen

Completed

Open-Label Natalizumab Safety Extension Study

Multiple Sclerosis

United States
Multiple Sclerosis Center of Northeastern New York

Active, not recruiting

Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

Multiple Sclerosis

United States
Biogen
Association for Functional Rehabilitation, Recreation and Applied Kinesiology...

Recruiting

TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants

Multiple Sclerosis

Czechia
Biogen

Terminated

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United Kingdom, United States, Canada, Belgium, Czech Republic, France, Germany, Netherlands
Biogen

Terminated

Natalizumab (Tysabri) Re-Initiation of Dosing (STRATA)

Relapsing-Remitting Multiple Sclerosis

Finland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
King's College London
South London and Maudsley NHS Foundation Trust

Completed

Inflammatory Response In Schizophrenia (IRIS)

Schizophrenia

United Kingdom
Biogen
Elan Pharmaceuticals

Completed

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
Kessler Foundation
St. Barnabas Medical Center

Recruiting

Examining Effects of Tysabri on Cognitive Fatigue Using fMRI

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen
Elan Pharmaceuticals

Terminated

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Rheumatoid Arthritis

United States, Canada
Case Comprehensive Cancer Center

Recruiting

Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

Pulmonary Metastatic Osteosarcoma (pOS)

United States
Biogen

Completed

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (TYNERGY)

Fatigue | Relapsing-Remitting Multiple Sclerosis

Sweden, Norway, Austria, Denmark
Washington University School of Medicine
Biogen; BioLineRx, Ltd.

Recruiting

Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Sickle Cell Disease

United States
Biogen

Completed

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (TYPIFI)

Relapsing Remitting Multiple Sclerosis

Portugal

3

Subscribe